Median lobe vs. complete gland holmium laser enucleation of the prostate: A propensity score matching

Amihay Nevo1, Scott M. Cheney2, Michael Callegari1, Jonathan P. Moore2, Karen L. Stern2, Michael A. Zell1, Haidar Abdul-Muhsin2, Mitchell R. Humphreys2

1University Hospitals Cleveland Medical Center, Urology Institute, Cleveland, OH, United States; 2Mayo Clinic, Department of Urology, Arizona, AZ, United States


Published online August 30, 2022

Corresponding author: Dr. Amihay Nevo, University Hospitals - Cleveland Medical Center, Cleveland, OH, United States; amihay.nevo@uhhospitals.org

***

ABSTRACT

Introduction: Benign prostatic hyperplasia (BPH) is a common condition affecting aging men. While holmium laser enucleation of the prostate (HoLEP) is one of the most effective treatments for BPH, variations of the procedure, such as median lobe HoLEP (MLHoLEP), are rarely reported. Here, we report our institution’s experience with pHoLEP.

Methods: Our institutional prospective database was queried for patients having undergone median or individual lateral lobe enucleation between 2007 and 2018. A control cohort of patients who underwent standard HoLEP (sHoLEP) was identified using 1:2 propensity score matching based on age, prostate size, maximal flow rate (Qmax), postvoid residual volume (PVR), and AUA symptom score (AUAss). Three and 12-month AUAss, PVR, and Qmax were compared.

Results: Forty-seven patients were identified as having undergone MLHoLEP. At three-month followup, AUAss (p<0.01) and incontinence rates (p=0.045) were lower for MLHoLEP patients, in addition to them having shorter operative (36.5 mins vs. 64.5 mins, p<0.01) and enucleation.

KEY MESSAGES

- Median lobe HoLEP could be offered as an equivalent to standard HoLEP within a selected group of patients.
- In our series, median lobe HoLEP was associated with shorter operative time, faster improvement in AUA symptom score and less early incontinence.
- Median lobe HoLEP represents a safe and effective treatment for appropriately selected patients.
(13.8 mins vs. 37 mins, p<0.01) times as compared to sHoLEP patients. No difference was noted between MLHoLEP and sHoLEP cohorts with respect to age, prostate volume, PVR, or Qmax. Significant improvement in AUAss, PVR, and Q max from baseline to three and 12 months was noted overall in both groups.

**Conclusions:** MLHoLEP could provide a surgical option with reduced operative time, quicker improvement in AUAss and restored continence in appropriately selected patients. Ultimately, MLHoLEP represents a safe and effective treatment option to select patients who may not be eligible for or face potential morbidity concerns associated with sHoLEP.

**INTRODUCTION**
Benign prostatic hypertrophy (BPH) is one of the most common conditions of aging men, affecting approximately 50% of men over the age of 50 and 88% of men in their 80’s. The disease often leads to bothersome lower urinary tract symptoms, which compromises quality of life and ultimately may require treatment.¹,² During the past 2 decades, holmium laser enucleation of the prostate (HoLEP) has demonstrated superior effectiveness, durability, and versatility when compared to other transurethral interventions.¹,³

First described in 1996, HoLEP was traditionally used for whole gland enucleation however few variations of the 3-lobe enucleation procedure have been studied in depth or detailed in the literature.⁴ Variations in other urologic procedures, within prostate cancer especially while anecdotal, have been shown to be successful, decrease morbidity all while providing therapeutic improvement.⁵ With regards to BPH procedures, studies have illustrated that patients undergoing hemi resection or standard TURP had similar improvement in post-void residual urine volume (PVR), AUA symptom score (AUAss), and maximal flow rate (Q max), however long term outcomes were not reported.⁶

While enucleation of the median lobe is considered the simplest portion of the procedure to learn, performing a median lobe–only HoLEP may potentially decrease the adoption and utilization barrier facilitating another surgical modality for providers to offer patients.¹,⁷ To the best of our knowledge, illustrating how modifications of the standard HoLEP (sHoLEP) may influence patient outcomes has not been described. With this in mind, we wished to explore and describe how the utilization of median lobe HoLEP (MLHoLEP) within our institution could potentially benefit patients.

**METHODS**
After obtaining approval from our institutional review board committee, we queried our institutions prospectively maintained BPH database for patients who underwent HoLEP at our institution from June 2007 through December 2018. We identified patients who underwent planned MLHoLEP, including enucleation of the median lobe or of one lateral lobe only.
Patients with Parkinson’s disease or multiple sclerosis were found to have unique preoperative or postoperative characteristics and were excluded from matching. Additionally, we excluded patients in whom only a MLHoLEP was performed in the setting of an aborted sHoLEP.

All HoLEP procedures were performed by a single supervising surgeon (MRH) using a 100W or 120W holmium: yttrium-aluminum-garnet laser platform with a 550nm end-fire laser fiber. A 26F continuous flow resectoscope with a laser bridge and a 7F stabilizing catheter was used to enucleate part or all of prostate consistent with the previously described technique.8 pHoLEP was considered, and at the surgeon’s discretion during the index procedure, when one of the following conditions were encountered clinically; obstruction likely secondary to a large median lobe, patients with history of pelvic radiation for prostate cancer, or in younger patients trying to preserve antegrade ejaculation.

Preoperative demographic, comorbidities, AUA symptom score (AUA ss), post void residual volume (PVR), Q max on uroflowmetry, as well as the indication for MLHoLEP were collected. Prostate volume was calculated from cross sectional imaging or from preoperative transrectal ultrasound when available. Intraoperative data included operative, laser, and enucleation times. Postoperative data included postoperative complication rates, hospital length of stay and catheterization, functional urinary parameters, post-HoLEP secondary interventions for BPH, bladder neck contracture, or urethral strictures. Urinary incontinence was defined as any urine leakage reported by the patient at their post-operative visit.

**Outcomes**

The study’s primary outcome was improvement in baseline functional parameters, including Q max, PVR, and AUA ss, at 3 and 12 months. Secondary outcomes were postoperative incontinence, the need for further interventions for persistent low urinary tract symptoms, and postoperative complications.

**Statistical analysis**

To control for various variables, we performed a propensity score matching with a 1:2 ratio with patients treated to sHoLEP. Continuous variables are described as the median and IQR. Categorical variables are described as the frequency and proportion. A longitudinal mixed model was used to compare the changes in urinary parameters over time in each group and between groups. All analyses were done using IBM SPSS version 25 (SPSS). Significance was assumed at the 0.05 level.

**RESULTS**

Of 1251 patients who underwent HoLEP during the study period, we identified 52 (4.2%) patients who underwent pHoLEP, of whom, 5 were excluded due to neuromuscular disorders. Of the remaining 47 patients, 45 underwent median lobe HoLEP, and 2 underwent right lobe-only HoLEP. The indications for MLHoLEP included isolated median or lateral lobe obstruction in 27 patients, patient’s wish to maintain ejaculation and/or continence in 12 patients, prior
radiotherapy for prostate cancer in 6 patients, and severe comorbidities that would increase the risk and perioperative morbidity associated with prolonged anesthesia in 2 patients.

In comparison to the whole cohort, MLHoLEP patients were younger (66 vs 70.7 years old, p=0.002), had smaller prostate volumes (36ml vs 78.1ml, p=0.001), and higher PVR (212 ml vs 160 ml, p=0.02). After propensity score matching, we identified a control group of 93 patients who underwent sHoLEP. Both groups were matched with respect to age, prostate volume, PVR, AUA ss, and Q max (Table 1). Patients who underwent MLHoLEP had shorter operative times (36.5 minutes vs 64.5 minutes, p<0.01), and shorter enucleation time (13.8 minutes vs 37 minutes, p<0.01) compared to sHoLEP. Postoperative catheter duration and length of stay were similar between groups. Thirty-day complication rate was 17% and 9.7% in the MLHoLEP and sHoLEP groups, respectively (p=0.3), and included hematuria (3 patients in each group), UTI (3 and 2 patients, respectively), and urinary retention (2 and 4 patients, respectively). Blood transfusion was not required in either group. Median follow-up time was 133 and 860 days in the MLHoLEP and sHoLEP groups, respectively (p=0.01).

In terms of urinary function parameters, there was a statistically significant improvement in AUA ss, PVR, and Q max in both groups (Table 2). These results were persistent at 3 months and 12 months postoperatively. There was a greater improvement in AUA ss in the MLHoLEP group than in the sHoLEP group after 3 months, but this trend was not maintained after 12 months. The improvement in PVR and Q max was similar between the groups (Figure 1). Early stress incontinence was more frequent in the sHoLEP group after 3 months (29% vs 12%, p=0.045), but was similar between the groups after 12 months.

In a subgroup analysis of the MLHoLEP group, prior radiation treatment was associated with an increased risk for incontinence after 3 months (50% vs 5.5%, p=0.01) but not after 12 months (25% vs 7%, p=0.4) in the radiation vs no-radiation groups, respectively.

In the follow-up period, 16 (10.7%) patients total underwent repeat intervention. One patient in each group underwent repeat BPH surgery (p=1). Urethral stricture developed in 1 and 2 patients from the MLHoLEP and sHoLEP groups, respectively (p=1), and bladder neck contracture occurred in 1 and 3 patients from the MLHoLEP and sHoLEP groups, respectively (p=1). Additional procedures included morcellation of retained tissue, clot evacuation, removal of prostatic calcifications, artificial urethral sphincter placement, Botox injection, and neuromodulation interstim placement, in one patient each. The median time for treatment of bladder neck contracture was 2 years (range 18 months-7 years) and for urethral stricture 1 year (range 90 days-2 years).

**DISCUSSION**

HoLEP is an established treatment for men with BPH. It has been proven to be effective in patients of all ages, prostates sizes and shapes, patients taking anticoagulant medications, and patients with acute or chronic urinary retention. The 2018 American Urological Association guidelines on surgical management of BPH/Lower urinary tract symptoms recommend HoLEP as a prostate size-independent treatment for BPH. We report our findings from the first study
Comparing partial with standard adenectomy using HoLEP. We found similar improvement in urinary parameters after MLHoLEP and sHoLEP, which was sustained after 12 months follow-up. Additionally, the reoperation rate was similarly low (2.1% and 1.1%) between the groups. These results highlight the versatility of MLHoLEP towards select patients.

With MLHoLEP, abbreviated operative times and less tissue removal, symptom relief and even improvement can be obtained all while preserving continence. This may be especially important for patients having previously undergone radiotherapy were external sphincter complex may be compromised and impacting quality of life. In the present study, early continence rates were found to be higher in the MLHoLEP group, versus one third of the patients who underwent sHoLEP who had temporary stress urinary incontinence after 3 months. Since patients were not routinely asked to fill out a validated ejaculatory functional questionnaire, their postoperative ejaculation status could not be determined.

Voiding parameters improved following surgery and were sustained after one year. The mean change in AUA ss, PVR, and Q max from baseline to 3 months was -14, -188 ml, and +9.5 ml/sec, respectively, similar to earlier prospective studies. Interestingly, greater improvement in AUA ss at 3 months but not after 12 months was found in the MLHoLEP group in comparison to the sHoLEP group. It is possible that higher laser energy used during sHoLEP, and a larger raw surface increased the irritation in the short term, and that these symptoms resolved after healing of the prostatic fossa. Other studies have also shown an immediate improvement in AUA ss after surgery, followed by moderate improvement up to 1 year of follow-up. Indeed, in a breakdown of the AUA ss 3 months after surgery, the only parameter that was different between the groups was urgency (median 0 vs 2, p=0.037).

The incontinence rate in the present study is noteworthy, since previous studies reported lower rates. Krambeck et. al. reported that 4.8% of the patients had stress incontinence after a follow-up of more than 1 year. There are several explanations to this difference. First, we defined incontinence as any leakage reported by the patient, thus including urge incontinence which occurs in 3 to 12% and patients after surgery. Second, asymptomatic patients are less likely return for follow-up, which increases the proportion of symptomatic patients engaged. Additionally, trainees were involved in the vast majority of the procedures, a factor that has been associated with increased postoperative urinary incontinence rates. Lastly, 6 patients in the MLHoLEP group received radiation for prostate cancer, representing 60% and 50% of the incontinent patients in this group. Had they been excluded from the analysis, the incontinence rate was 4.8% and 7.1% after 3 and 12 months, respectively.

Several groups of patients are predisposed to incontinence following bladder outlet procedures. Studies have shown that some degree of permanent urinary incontinence developed in 33% and 70% of patient undergoing brachytherapy or external beam radiotherapy for prostate cancer, respectively, likely, by compromising the urinary sphincters or the urethra itself. In the present study, half of the patients undergoing MLHoLEP following radiation treatment reported some degree of incontinence. Since the control group did not contain patients with prior
radiation treatment, we could not determine if the incontinence rate following sHoLEP was higher. Our results are in line with more recent studies. Only one patient, who had urinary urge incontinence before the surgery continued to have incontinence postoperatively.

The durable results of the HoLEP procedure have been attributed to complete removal of the adenoma rather than its resection. A concern when performing partial adenectomy is the rate of repeat surgery. Earlier studies have shown low but variable retreatment rates in sHoLEP patients. Krambeck et. al. reported only one patient (0.1%) who underwent repeat treatment due to bleeding nodular growth within long-term results of 1065 HoLEPS. Elzayat et. al similarly reported a low re-treatment rate of 4.2% among 118 patients, with greater than 4-year follow-up on their initial experience with HoLEP. The re-treatment in this case was associated with the steep procedural learning curve. In the present study, re-treatment for BPH was performed in one patient in each group, but the follow-up time was significantly shorter in the MLHoLEP group. It is possible that with longer follow-up, more patients may require re-treatment. This high rate can be partially attributed to the high-volume teaching environment at our institute, but there is little doubt that leaving adenomatous tissue increases the risk for persistent or recurrent urinary symptoms. Nevertheless, this limitation of MLHoLEP should be discussed with patients prior to surgery in which case they may choose to proceed with or pursue whole gland enucleation.

Our study is limited by the small sample size of patients having undergone MLHoLEP but remains the largest reported cohort within the literature to our knowledge. It also shares the same limitations traditionally associated with any retrospective analysis. The median prostate size in our study was small, and only 8 patients had prostates larger than 80 cc. As such, it is possible that the results are not generalizable to patients with larger glans. In addition, Mayo Clinic Hospital in Phoenix, Arizona, is a tertiary care center with many patients who come for urological evaluation and treatment from more remote locations. Often, patients seek follow-up closer to home with community urologist, limiting the availability of longitudinal long-term follow-up data. Additional limitations stem from our criteria for MLHoLEP consideration; these considerations are limited and may not appropriately recognize all patients that could be eligible or who would benefit from partial over standard enucleation. Lastly, while we performed matching for multiple variables, we did not control for prostate anatomy, which is an important factor when considering appropriate BPH surgical approach. We do not advise doing MLHoLEP in patients without a prominent single lobe obstruction.

Several reports describe variations on the traditional HoLEP technique, yet MLHoLEP is not included and can be a highly useful procedure in certain circumstances. Examples of select patients for which MLHoLEP may be indicated could include those with significant comorbidities placing them at increased risk of perioperative morbidity and mortality during prolonged anesthesia or operative procedures. Even young, active patients might benefit from partial treatment by limiting transitory stress urinary incontinence and preserving antegrade ejaculation.
CONCLUSIONS
Median Lobe HoLEP is equivalent to sHoLEP in this selected group of patients with small prostates, and is associated with shorter operating times, faster improvement in AUA ss, and less temporary stress urinary incontinence than sHoLEP. MLHoLEP represents a safe and effective treatment for patients who may not prefer or be able to tolerate any risks or outcomes associated with a standard HoLEP procedure.
References


Figures and Tables

**Figure 1.** Changes in (A) postvoid residual volume; (B) maximal flow rate; and (C) International Prostate Symptom Score at 3 and 12 months after surgery.
Table 1. Comparison of partial vs. standard HoLEP patient characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>pHoLEP (n=47)</th>
<th>sHoLEP (n=93)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (IQR)</td>
<td>66 (60–72)</td>
<td>66 (63–71)</td>
<td>0.7</td>
</tr>
<tr>
<td>Median preoperative prostate volume (IQR)</td>
<td>36 (27.6–47.3)</td>
<td>35.5 (28.5–46.3)</td>
<td>0.7</td>
</tr>
<tr>
<td>Prior BPH surgery (%)</td>
<td>3 (6.8)</td>
<td>14 (15)</td>
<td>0.17</td>
</tr>
<tr>
<td>Prior radiation for prostate cancer (%)</td>
<td>6 (13)</td>
<td>0 (0%)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Urinary retention (%)</td>
<td>11 (23.4)</td>
<td>16 (17.2)</td>
<td>0.52</td>
</tr>
<tr>
<td>Median procedure time in minutes (IQR)</td>
<td>36.5 (25.2–42.7)</td>
<td>64.5 (48–92)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Median enucleation time in minutes (IQR)</td>
<td>13.8 (6.6–20.2)</td>
<td>37 (24.6–51)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Mean catheterization time in days (IQR)</td>
<td>2 (1–3)</td>
<td>2 (1–3)</td>
<td>0.8</td>
</tr>
<tr>
<td>Median length of stay in days (IQR)</td>
<td>1.5 (1–3)</td>
<td>2 (2–3)</td>
<td>0.014</td>
</tr>
<tr>
<td>30-days complications (%)</td>
<td>8 (17)</td>
<td>9 (9.7)</td>
<td>0.3</td>
</tr>
<tr>
<td>3-month urinary leak (%)</td>
<td>5 (12)</td>
<td>26 (29)</td>
<td>0.045</td>
</tr>
<tr>
<td>12-month urinary leak (%)</td>
<td>2/15 (13.3)</td>
<td>9/70 (12.8)</td>
<td>1</td>
</tr>
<tr>
<td>Bladder neck contracture (%)</td>
<td>1 (2.1)</td>
<td>3 (3.2)</td>
<td>1</td>
</tr>
<tr>
<td>Urethral stricture (%)</td>
<td>1 (2.1)</td>
<td>2 (2.1)</td>
<td>1</td>
</tr>
<tr>
<td>Repeat BPH surgery (%)</td>
<td>1 (2.1)</td>
<td>1 (1.1)</td>
<td>1</td>
</tr>
</tbody>
</table>

BPH: benign prostatic hyperplasia; HoLEP: holmium laser enucleation of the prostate; IQR: interquartile range; p: partial; s: standard.
Table 2. Baseline, short- and long-term outcomes between the partial vs. complete HoLEP treatment groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>3 months</th>
<th>p</th>
<th>12 months</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUA score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pHoLEP</td>
<td>20 (12–27)</td>
<td>4 (3–8)</td>
<td>&lt;0.01</td>
<td>8 (1–10)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>sHoLEP</td>
<td>21 (17–26)</td>
<td>8 (5–13)</td>
<td>&lt;0.01</td>
<td>9 (6–10)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>PVR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pHoLEP</td>
<td>212 (97–432)</td>
<td>80 (38–142)</td>
<td>&lt;0.01</td>
<td>83 (7–208)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>sHoLEP</td>
<td>149 (65–358)</td>
<td>25 (4–77)</td>
<td>&lt;0.01</td>
<td>103 (47–127)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Qmax</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pHoLEP</td>
<td>7 (4–10)</td>
<td>16 (11–26)</td>
<td>&lt;0.01</td>
<td>17 (10–29)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>sHoLEP</td>
<td>8 (4–14)</td>
<td>18 (10–23)</td>
<td>&lt;0.01</td>
<td>18 (13–22)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Medians and (IQR) presented. P-values in comparison to baseline. AUA: American Urological Association; HoLEP: holmium laser enucleation of the prostate; p: partial; PVR: postvoid residual; Qmax: maximal flow rate; s: standard.